InnoCan Pharma (INNO) Q2 2025 earnings summary

Executive summary

• Achieved a positive swing in operating profitability for the first half of 2025, despite challenging market conditions and global trade tariffs.

• Focused on strategic execution in multiple target markets, emphasizing opioid-free chronic pain relief and growth in the Consumer Wellness segment.

• Progressed toward a U.S. public offering, applying to list shares and warrants on the Nasdaq Capital Market.

Financial highlights

• Revenues decreased 4% year-over-year to $14.8M for H1 2025, compared to $15.4M in H1 2024.

• Gross profit declined 4.9% to $13.3M from $14M year-over-year.

• Operating profit improved to $0.885M, a 130% increase from an operating loss of $0.68M in H1 2024.

Outlook and guidance

• Anticipates new opportunities from the proposed U.S. public offering and Nasdaq listing.

• Continues to advance the LPT-CBD platform for chronic pain, with late pre-clinical development showing sustained pharmacokinetics and favorable tolerability.

• Exploring strategic expansion of distribution channels and launching innovative consumer products aligned with market trends.